140 reports of this reaction
1.9% of all PILOCARPINE HYDROCHLORIDE reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for PILOCARPINE HYDROCHLORIDE, manufactured by Advanz Pharma (US) Corp.. There are 140 FDA adverse event reports linking PILOCARPINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 1.9% of all 7,486 adverse event reports for this drug.
Patients taking PILOCARPINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for PILOCARPINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for PILOCARPINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 140 FDA reports for PILOCARPINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.9% of all adverse event reports for PILOCARPINE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking PILOCARPINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.